Skip to main content

Advertisement

Novel treatments for rare rheumatologic disorders: analysis of the impact of 30 years of the US orphan drug act

Article metrics

Abstract

Background

Rare rheumatologic diseases are a heterogeneous group of conditions associated with high morbidity. As a whole group, rare rheumatologic diseases afflict millions of people demanding for effective therapies. Therefore, we analyzed the impact of the US Orphan Drug Act on the development of anti-rheumatic orphan drugs.

Methods

Analysis of the FDA database for orphan drug designations.

Results

In the last three decades, out of 77 orphan drug designations, 14 orphan drug approvals were granted by the FDA for the treatment of rare rheumatologic disorders, i.e. juvenile idiopathic arthritis (N = 5), cryopyrin-associated periodic syndromes (N = 3), uveitis (N = 3), familial Mediterranean fever (N = 1), anti-neutrophil cytoplasmic antibody-associated vasculitis (N = 1), and xerostomia and keratoconjunctivitis sicca in Sjögren’s syndrome (N = 1). Mean time (standard deviation) from designation to approval was 3.9 (2.81) [range 1 … 12] years. Number of FDA-approved small molecules (N = 6, 43 %) and biologics (N = 8, 57 %) was comparable. Almost every fifth (19 %) orphan drug designation was withdrawn. Despite the rarity of conditions, 13/14 pivotal studies were randomized controlled trials.

Conclusions

Orphan drug development is challenging: thirty years of US orphan drug act supported the development and FDA approval of 14 orphan drug programs with anti-rheumatic compounds for six rheumatologic diseases.

Background

Rheumatologic diseases are associated with high morbidity leading to reduced quality of life, potentially life-long disability, and premature death. Although rare in individuals, as a whole group rare rheumatologic disorders afflict a large group of people [1, 2]. Furthermore, many rare autoinflammatory conditions, such as systemic lupus erythematodes, dermatomyositis, scleroderma, vasculitis, periodic fever syndromes, nonbacterial osteomyelitis, or uveitis can manifest already in childhood. For example, the prevalence of juvenile idiopathic arthritis (JIA), having its onset before 16 years of age, varies between 3.8 and 400 per 100,000 [1, 3]. Considering the definition for an orphan disease in general as a condition affecting less than 7.5 people in 10.000 or less than 200.000 in the US or less than five in 10.000 in the European Union, orphan drug development is tremendously challenged by small sample sizes [2, 4, 5]. In addition, highly variable manifestations of rheumatologic diseases and onset in childhood complicate drug development. The US Orphan Drug Act was passed in 1983 to stimulate the investment into development of treatments for rare diseases by granting various incentives, such as 7 years’ marketing exclusivity, tax credit for 50 % of clinical trial costs, protocol assistance, Food and Drug Administration (FDA) fee waiver, and orphan grants programs [4]. The impact of the US orphan drug act on successful drug development for the treatment of rare rheumatologic diseases has not been systematically analyzed. We therefore analyzed how many orphan drugs were designated and subsequently approved by the FDA between 1983 and 2013 to treat rare rheumatologic diseases.

Methods

Search strategy

For quantitative analysis, we searched the publically available FDA database for orphan drug designations [6] using the following disease entities as search terms (terms for pediatric rheumatologic diseases in alphabetical order [7]): arthritis, antiphospholipid antibody syndrome, Behçet syndrome, collagenosis, CREST syndrome (calcinosis, Raynaud’s phenomenon, esophageal dysmotility, sclerodactyly and telangiectasia), childhood and adolescence arthritis, CAPS (cryopyrin-associated periodic syndromes) such as CINCA/NOMID (chronic infantile neurologic cutaneous and articular syndrome/neonatal-onset multisystem inflammatory disease), MWS (Muckle-Wells syndrome) or FCAS (familial cold autoinflammatory syndrome), cutaneous leukocytoclastic vasculitis, dermatomyositis, diffuse sclerosis, drug induced lupus erythematosus, enthesitis-related arthritis, eosinophilic fasciitis (Shulman syndrome), eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome), familial cold autoinflammatory syndrome, familial Mediterranean fever, Felty syndrome, granulomatosis with polyangiitis, Hyper IgD syndrome, idiopathic uveitis, IgA vasculitis (Henoch - Schönlein purpura), infantile sarcoidosis, isolated sacroiliitis, juvenile ankylosing spondylitis, juvenile idiopathic arthritis, Kawasaki syndrome, limited systemic sclerodermia, localized scleroderma, lupus, microscopic polyangiitis, mixed connective tissue disease, non-bacterial osteitis, oligoarthritis, periodic fever syndromes, PFAPA syndrome (periodic fever, aphthous stomatitis, pharyngitis, adenitis), polyarteritis nodosa, polymyositis, primary angiitis of the central nervous system, psoriatic arthritis, relapsing polychronditis, rheumatoid factor negative polyarthritis, rheumatoid factor positive polyarthritis, Sharp syndrome, Sjögren’s syndrome, spondyloarthritis due to chronic inflammatory intestinal disorders, spondyloarthritis due to psoriasis, spondylodiscitis, spondylolisthesis, spondylolysis, systemic arthritis, systemic lupus erythematosus, systemic sclerosis, Takayasu arteritis, transient synovitis, TRAPS (tumor necrosis factor receptor associated periodic syndrome), undifferentiated juvenile idiopathic arthritis, and vasculitis (e.g., Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis). Non-English alphabet letters such as umlaut were searched with alternative spellings (e.g., ö was also entered as both o and oe). Acronyms were searched by both the acronym and the full wording. Disease terms with more than one word were searched with the full disease term and with each individual component of the term, e.g., “juvenile idiopathic arthritis” was searched as “juvenile”, “idiopathic”, “arthritis”, and “juvenile idiopathic arthritis”. All search results were subsequently checked for plausibility. All data entries from 1/1/1983 until 12/31/2013 were considered. Original terms from the FDA orphan drug database or FDA label were used to describe designated or approved indications to conform to source data.

Definitions

Identified compounds were categorized either according to their drug class or pharmacologic category. Within the respective classification, remaining compounds that could not be clearly allocated to a particular category were grouped as others. For classification according to their drug class, the compounds were accounted as small molecules or biologics. A small molecule was defined as a low-weight molecule (typically <1,000 Da) which is usually derived from chemical synthesis and can be fully characterized by analytical techniques [8, 9]. In contrast, biologics are large-molecular weight and structurally complex proteins that are derived from living cells through biotechnological processes (e.g., antibody methods, controlled gene expression or recombinant DNA) [8, 9]. Biologics were further differentiated into antibodies and fusion proteins. For classification according to pharmacologic category, compounds were grouped according to their mechanism of action which was gained from the FDA label for approved compounds. For the assessment of the putative mechanism of action of compounds that were not approved by the FDA, we started from the designated indication and selected the most likely mechanism of action causing the intended effect.

Statistics

Data were analyzed by standard methods of descriptive statistics with SAS Enterprise Guide version 5.1 (SAS, Cary, NC, USA). Continuous variables are presented as means, standard deviations, and ranges. For categorical variables, N and percentages were calculated. Time-to-approval was calculated as the time span from orphan drug designation to FDA approval.

Results

Orphan drug designations

Overall, 77 orphan drug designations were granted for 64 different compounds between 1983 and 2013 (Fig. 1, Table 1). The first orphan drug designations were granted in 1986 for two compounds, i.e. guanethidine monosulfate (for the treatment of moderate to severe reflex sympathetic dystrophy and causalgia) and dimethyl sulfoxide (for the treatment of cutaneous manifestations of scleroderma). Both designations were subsequently withdrawn. Most designations per year were granted in 2011 (N = 8). When analyzed according to drug classes, 33/77 (43 %) designations were granted for 23 different biologics, 28/77 (36 %) for 27 different small molecules and 14/77 (18 %) designations for others representing 12 different compounds (Table 1). With two designations the drug class of the compounds was unknown (i.e., AI-RSA and Interleukin-1 Trap). Biologics were further differentiated into chimeric antibodies (4/33), human antibodies (10/33), humanized antibodies (8/33), unspecified antibodies (2/33) (i.e., human anti-tumor necrosis factor alpha monoclonal antibody and monoclonal antibody for immunization against lupus nephritis), fusion proteins (4/33), and other biologics (5/33) (i.e., anakinra, hanferon, interferon beta-1a, interleukin-1 receptor antagonist human recombinant, and a DNA plasmid pVGI.1 (VEGF2)) (Fig. 2).

Fig. 1
figure1

Orphan drugs for rare rheumatologic disorders – number of orphan drug designations (open box) and FDA approvals (black box) per year

Table 1 Drug class and indications of designated anti-rheumatic orphan drugs
Fig. 2
figure2

Orphan drugs for rare rheumatologic disorders: year of orphan drug designation by technology platform

FDA approvals

Between 1983 and 2013, 14/77 (18 %) orphan drug designations received FDA approval representing 13 different compounds, because canakinumab was approved for two indications (Table 2, Fig. 1). Five drugs were approved for JIA, three for CAPS, three for uveitis, one for familial Mediterranean fever, one for ANCA associated vasculitis, and one for xerostomia and keratoconjunctivitis sicca in Sjögren's syndrome patients (Table 2). The first approved orphan compound for a rare rheumatologic condition was pilocarpine hydrochloride for treating xerostomia and keratoconjunctivitis in Sjögren’s syndrome in 1998. Mean time (standard deviation) from designation to approval was 3.9 (2.81) [range 1 … 12] years. Divided according to drug classes, 6/14 (43 %) FDA orphan drug approvals comprised small molecules and 8/14 (57 %) FDA orphan drug approvals were biologics. The time between orphan drug designation and time of approval was similar for biologics and small molecules (Fig. 3). Most pivotal trials were randomized controlled trials (Table 2).

Table 2 Orphan drugs for the treatment of rare rheumatologic disorders approved by the FDA between 1983 and 2013
Fig. 3
figure3

Orphan drugs for rare rheumatologic disorders – time to FDA approval. a by drug class. b by disease. Lines indicate means

Withdrawn orphan drug designations

Overall, 15/77 (19 %) orphan drug designations (14 compounds) were withdrawn before approval (Table 3). The reasons for withdrawals were not captured in the FDA database.

Table 3 Withdrawn orphan drug designations between 1983 and 2013 for compounds intended to treat rare rheumatologic disorders

Pharmacologic categories of designated orphan drugs

Designated compounds were immunomodulators, such as immunosuppressants, immunostimulants, tolerogens, or compounds with unspecified immunomodulatory properties, Nonsteroidal anti-inflammatory drugs (NSAIDs), expectorants, antibiotics, and angiogenic, antiarrhythmic, diagnostic, parasympathomimetic, and sympatholytic agents.

Design of pivotal clinical trials and endpoints leading to FDA approval

Only one pivotal trial, i.e. the study of anakinra for the treatment of neonatal onset inflammatory disease, was open label (Table 2). The other 12 approved compounds were studied for 13 indications in randomized controlled trials in which withdrawal designs were common. Colchicine received approval for the treatment of familial Mediterranean fever based on data available in the published literature. Most clinical trials were rather small and involved both children and adults. Studies were either uncontrolled (i.e., anakinra) or controlled with placebo (i.e., colchicine, rilonacept, canakinumab in both indications, etanercept, pilocarpine, adalimumab, and tocilizumab), sham procedure (i.e., dexamethasone intravitreal implant), before after control (i.e., fluocinolone acetonide intravitreal implant), or active control (i.e., meloxicam vs. naproxen, difluprednate ophthalmic solution vs. prednisolone, rituximab vs. cyclophosphamide in a non-inferiority design). Etanercept was studied as add-on therapy to an NSAID and/or prednisone.

Discussion

In 2013, 77 orphan drug designations for rare rheumatologic disorders were granted by the FDA whereof 14 resulted in FDA approval comprising 13 different substances. Almost every fifth designation was withdrawn, mostly with unknown reasons. However, with etanercept safety reasons may have played a role in withdrawal: etanercept was studied in Wegener’s granulomatosis with a higher incidence of malignancies observed in the etanercept group compared with standard therapy [10, 11]. The success rate to achieve marketing approval in rheumatologic orphan drug development is comparable to overall success rates in orphan drug development, i.e. 14 % [12]. In general, failure of orphan drug applications are mainly attributed to the pivotal clinical trial design (e.g. choice of endpoints and target population), inexperience in orphan drug development of sponsors, and a low level of interaction with the FDA (e.g. protocol assistance) [13]. These factors seem to be interdependent because inexperienced sponsors may choose inadequate pivotal clinical trial designs and may benefit most from FDA protocol assistance. The reasons why compounds were withdrawn or not approved e.g. lack of efficacy, safety issues or due to commercially driven decisions, are not available in the FDA database. Although, this information would be of value for the clinician as it may protect patients from unnecessary exposure to further research and should be made publically available.

By definition, drug development in orphan diseases is challenged by small sample sizes [5]. In addition, disease-specific factors, such as the prevalence, disease class, and scientific output, influence success rates in orphan drug development [14]. Rheumatologic diseases include complex pathomechanisms which complicates identification of potential drug targets. Most of the designated compounds target autoimmune and subsequent inflammatory reactions. Particularly, immunomodulators play a pivotal role in disease modification by modulating various pathophysiologically relevant targets in the inflammatory process e.g., antibodies against specific surface antigens on lymphocytes, glucocorticoids that inhibit transcription of inflammatory cytokines such as interleukins and TNF-alpha, decoy receptors, or antagonists for receptors of inflammatory proteins. In addition, compounds that relieve symptoms associated with rheumatologic diseases were designated as orphan drugs, such as pilocarpine-HCl which increases lacrimal secretion and hence alleviates xerostomia and keratoconjunctivitis sicca in Sjögren’s syndrome patients. Nitric oxide (NO), a biomarker of airway inflammation, received orphan drug designation for the diagnosis of sarcoidosis. However, the diagnostic clinical trial could not detect a difference in exhaled NO levels between patients and controls [15]. All remaining 76 orphan drug designations for rheumatologic conditions were of therapeutic purpose.

Orphan drugs for rheumatologic disease hold indications in other disease areas by targeting pathways also relevant in other conditions. For example, rituximab, which is a selective immunosuppressant targeting CD20 surface proteins on B-lymphocytes, is also approved for treatment of Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia [16]. In contrast, orphan drugs for lysosomal storage disorders target a specific pathway that is unique for the respective conditions. For instance, although Fabry disease and Gaucher disease are sphingolipidoses, the therapeutic enzyme for Fabry disease (agalsidase alfa or beta) is different to the enzyme replacement therapy in Gaucher disease (recombinant glucocerebrosidase) [17, 18].

The choice for or against an orphan drug development pathway can vary within same disease entity: both tocilizumab and canakinumab are approved for the treatment of systemic juvenile idiopathic arthritis. Of interest, the orphan program with canakinumab consisted of two studies with N = 261 participants followed for 4 and 48 weeks, whereas the non-orphan tocilizumab program had only one clinical trial and involved N = 112 subjects with a study duration of 12 weeks [19, 20]. Sample size and design of pivotal clinical trials for the approved rheumatologic orphan drug indication varied. Most studies were randomized placebo controlled trials which corroborates that drug development in rare diseases is possible at a high level of evidence. The FDA guidance for industry for the development of drug products for the treatment of rheumatoid arthritis recommends the use of efficacy endpoints capturing clinical remission and prevention of structural damage, suggests to limit the use of placebo both in short-term and long-term trials, and encourages study designs with active comparators [21]. Endpoints in clinical trials of the orphan drugs approved for rheumatologic disorders included categorical variables such as number of attacks in familial Mediterranean fever under colchicine, rate of recurrence of uveitis under fluocinolone acetonid intravitreal implant, disease scores such as vitreous haze score or anterior chamber cell grade for uveitis under difluprednate ophthalmic emulsion or dexamethasone intravitreal implant, multisystem composite disease scores, such as the Birmingham Vasculitis Activity Score for Granulomatosis with Polyangiitis [22] or the American College of Rheumatology Pediatric 30 criteria for improvement which comprises subjective, objective and biochemical components [23]. For the future, it would be desirable to capture the impact of the tested intervention on patients’ needs by including patient centered outcome measures such as the Canadian Occupational Performance Measure as clinical trial endpoints where possible [24]. As signals may not become evident or may not be detectable in the initial small and short clinical trials (Table 2), it is desirable to follow-up on the long-term effectiveness and safety outcome in systematic disease registries after drug approval. Compared to oncological orphan drugs with a shorter time to approval, orphan drug designations in rheumatologic diseases seem to be either set earlier in the drug development process or the process from designation to approval may be slower [12]. In general, orphan drug designations are granted during the final steps of the drug development process [25]. Although, the orphan drug designation is arbitrary in the drug development process, time to approval allows an approximate estimation of orphan drug approvals of currently filed designated orphan drugs.

This quantitative analysis has several limitations. We made the assumption that the designation of a compound as an orphan drug was considered a surrogate for the intent to develop a drug for a disease. However, not all manufacturers may seek orphan drug designation by the FDA and information may therefore not be transparent, e.g. due to patent considerations. The amount of designations might be prone to bias since one compound might be designated as an orphan drug several times, e.g. interleukin 1-trap and rilonacept. The true duration of the development program may not be reflected by time to approval because the time of orphan designation may be arbitrary in the drug development process and, thus does not allowing a comparison between orphan drug development and non-orphan drug development. Data from the European Medicine Agency data were not formally analyzed. We chose this approach, because the European orphan legislation was only introduced in 2000. Therefore, the European database is less comprehensive compared to the one hosted by the FDA. However, drug development for orphan conditions is a global effort. EMA orphan drug designations show similar trends (data not shown). Therefore, the present formal analysis of the FDA data and their impact for patients around the world are considered generalizable.

Conclusions

In conclusion, orphan drug development is challenging: 30 years of US orphan drug act delivered 14 orphan drug programs with anti-rheumatic or supportive compounds for six rare rheumatologic conditions. Although, rarity and diversity of conditions account for the small sizes all but one pivotal study were randomized controlled trials.

Abbreviations

ANCA:

anti-neutrophil cytoplasmic antibody

CAPS:

cryopyrin-associated periodic syndromes

CINCA:

chronic infantile neurologic cutaneous and articular syndrome

CREST syndrome:

calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia

DNA:

desoxyribonucleic acid

FCAS:

familial cold autoinflammatory syndrome

FDA:

Food and Drug Administration

IgA:

immunglobulin A

IgD:

immunglobulin D

JIA:

juvenile idiopathic arthritis

MWS:

Muckle-Wells Syndrome

NO:

nitric oxide

NOMID:

neonatal-onset multisystem inflammatory disease

NSAID:

nonsteroidal anti-inflammatory drug

PFAPA syndrome:

periodic fever, aphthous stomatitis, pharyngitis, adenitis

TRAPS:

tumor necrosis factor receptor associated periodic syndrome

VEGF2:

vascular endothelial growth factor 2

References

  1. 1.

    Prevalence of rare diseases: Bibliographic data », Orphanet Report Series, Rare Diseases collection, July 2015,Number 1: Diseases listed in alphabetical order. http://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_alphabetical_list.pdf. Accessed 20 October 2015

  2. 2.

    Schieppati A, Henter JI, Daina E, Aperia A. Why rare diseases are an important medical and social issue. Lancet. 2008;371:2039–41.

  3. 3.

    Thierry S, Fautrel B, Lemelle I, Guillemin F. Prevalence and incidence of juvenile idiopathic arthritis: a systematic review. Joint Bone Spine. 2014;81:112–7.

  4. 4.

    Haffner ME, Torrent-Farnell J, Maher PD. Does orphan drug legislation really answer the needs of patients? Lancet. 2008;371:2041–4.

  5. 5.

    Buckley BM. Clinical trials of orphan medicines. Lancet. 2008;371:2051–5.

  6. 6.

    FDA. Search Orphan Drug Designations and Approvals. http://www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm. Accessed 22 July 2014

  7. 7.

    Minden K, Niewerth M, Listing J, Zink A, German Study Group of Pediatric R. Health care provision in pediatric rheumatology in Germany--national rheumatologic database. J Rheumatol. 2002;29:622–8.

  8. 8.

    Stanczyk J, Ospelt C, Gay S. Is there a future for small molecule drugs in the treatment of rheumatic diseases? Curr Opin Rheumatol. 2008;20:257–62.

  9. 9.

    Rak Tkaczuk KH, Jacobs IA. Biosimilars in oncology: from development to clinical practice. Semin Oncol. 2014;41 Suppl 3:S3–12.

  10. 10.

    FDA. ENBREL, BLA no. 103795, label. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103795s5548lbl.pdf. Accessed 20 October 2015

  11. 11.

    Stone JH, Holbrook JT, Marriott MA, Tibbs AK, Sejismundo LP, Min YI, et al. Solid malignancies among patients in the Wegener’s Granulomatosis Etanercept Trial. Arthritis Rheum. 2006;54:1608–18.

  12. 12.

    Stockklausner C, Lampert A, Hoffmann GF, Ries M. Novel Treatments For Rare Cancers: The U.S. Orphan Drug Act Is Delivering - A Cross-Sectional Analysis. Oncologist 2016;21(4):487-93.

  13. 13.

    Heemstra HE, Leufkens HG, Rodgers RP, Xu K, Voordouw BC, Braun MM. Characteristics of orphan drug applications that fail to achieve marketing approval in the USA. Drug Discov Today. 2011;16:73–80.

  14. 14.

    Heemstra HE, van Weely S, Büller HA, Leufkens HG, de Vrueh RL. Translation of rare disease research into orphan drug development: disease matters. Drug Discov Today. 2009;14:1166–73.

  15. 15.

    Wilsher ML, Fergusson W, Milne D, Wells AU. Exhaled nitric oxide in sarcoidosis. Thorax. 2005;60:967–70.

  16. 16.

    FDA. RITUXAN, BLA no. 103705, label. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/103705s5414lbl.pdf. Accessed 20 October 2015

  17. 17.

    Mechler K, Mountford WK, Hoffmann GF, Ries M. "Pressure for drug development in lysosomal storage disorders - a quantitative analysis thirty years beyond the US orphan drug act. Orphanet J Rare Dis. 2015 Apr 18.

  18. 18.

    Brady RO. Enzyme replacement therapy: conception, chaos and culmination. Philos Trans R Soc Lond B Biol Sci. 2003;358:915–9.

  19. 19.

    FDA. ILARIS, BLA no. 125319, label. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125319s062lbl.pdf. Accessed 20 October 2015

  20. 20.

    FDA. ACTEMRA, BLA no. 125276, label http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125276s092lbl.pdf. Accessed 20 October 2015

  21. 21.

    FDA. Guidance for Industry Rheumatoid Arthritis: Developing Drug Products for Treatment. http://www.fdanews.com/ext/resources/files/archives/62813-01/06-07-13-RA.pdf. Accessed 20 October 2015

  22. 22.

    Stone JH, Hoffman GS, Merkel PA, Min YI, Uhlfelder ML, Hellmann DB, et al. A disease-specific activity index for Wegener’s granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum. 2001;44:912–20.

  23. 23.

    Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40:1202–9.

  24. 24.

    van de Ven-Stevens LA, Graff MJ, Selles RW, Schreuders TA, van der Linde H, Spauwen PH, Geurts AC. Instruments for assessment of impairments and activity limitations in patients with hand conditions: A European Delphi study. J Rehabil Med. 2016;47:948–56.

  25. 25.

    Field MJ, Boat TF. Rare diseases and orphan products: Accelerating research and development. Washington: National Press (US); 2010.

  26. 26.

    FDA. SALAGEN, NDA no. 020237, label. http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/020237s012lbl.pdf. Accessed 20 October 2015

  27. 27.

    FDA. OZURDEX, NDA no. 022315, label. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022315s009lbl.pdf. Accessed 20 October 2015

  28. 28.

    FDA. RETISERT, NDA no. 021737, label http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021737s019.pdf. Accessed 20 October 2015

  29. 29.

    FDA. MOBIC, NDA no. 020938, label. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020938s022lbl.pdf. Accessed 20 October 2015

  30. 30.

    FDA. ARCALYST, BLA no. 125249, label. http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/125249lbl.pdf. Accessed 20 October 2015

  31. 31.

    FDA. HUMIRA, BLA no. 125057, label. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125057s367lbl.pdf. Accessed 20 October 2015

  32. 32.

    FDA. COLCRYS, NDA no. 022351, label. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022351lbl.pdf. Accessed 20 October 2015

  33. 33.

    FDA. DUREZOL, NDA no. 022212, label. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022212s012lbl.pdf. Accessed 20 October 2015

  34. 34.

    FDA. KINERET, BLA no. 103950, label. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/103950s5150lbl.pdf. Accessed 20 October 2015

Download references

Author information

Correspondence to Markus Ries.

Additional information

Competing interests

AL received a personal scholarship from the “Dr. August and Dr. Anni Lesmüller foundation”. MR received consultancy fees or research grants from Alexion, GSK, Oxyrane and Shire. TL and GFH report not conflict of interest.

Authors’ contributions

TL has contributed to the acquisition, analysis, and interpretation of the data, critical revision of the manuscript for important intellectual content, and material support. AL has contributed to the acquisition, analysis, and interpretation of the data, drafting of the manuscript, critical revision of the manuscript for important intellectual content, and statistical analysis. GFH contributed to the interpretation of the data, critical revision of the manuscript for important intellectual content, and material support. MR has conceptualized the design of the study, contributed to the acquisition, analysis, and interpretation of the data, drafting of the manuscript, critical revision of the manuscript for important intellectual content, and statistical analysis. All authors approved the final version to be published and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All authors confirm that they had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Keywords

  • Orphan drug act
  • Orphan drug development
  • Rare disease
  • Rare rheumatologic disease